<DOC>
	<DOCNO>NCT00040859</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine oxaliplatin capecitabine treat patient advanced esophageal cancer stomach cancer .</brief_summary>
	<brief_title>Oxaliplatin Capecitabine Treating Patients With Advanced Esophageal Cancer Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine objective tumor response rate patient advance adenocarcinoma esophagus , gastroesophageal junction , gastric cardia treat oxaliplatin capecitabine . Secondary - Determine time progression overall survival patient treat regimen . - Determine toxic effect regimen patient . - Assess quality life patient treat regimen . OUTLINE : Patients receive oxaliplatin IV 2 hour day 1 oral capecitabine twice daily day 1-14 . Treatment repeat every 21 day least 2 course absence disease progression unacceptable toxicity . Patients complete response ( CR ) receive 2 additional course CR . Quality life assess baseline every 3 week ( prior course chemotherapy ) . Patients follow every 3 month 1 year every 6 month 2 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma esophagus , gastroesophageal junction , gastric cardia potentially curative significant palliative therapy exist Unresectable disease Gastric cardia define 5 cm gastroesophageal junction stomach Measurable disease No known CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great upper limit normal ( ULN ) AST great 3 time ULN Alkaline phosphatase great 2 time ULN Renal : Creatinine great 1.5 time ULN Creatinine clearance least 60 mL/min Cardiovascular : No New York Heart Association class III IV heart disease Other : Able swallow capecitabine No unresolved gastrointestinal bleeding No uncontrolled infection No chronic debilitate disease No peripheral neuropathy grade 2 great No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer adequately treat noninvasive carcinoma Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy biological therapy recurrent metastatic disease No concurrent biologic agent Chemotherapy : No prior chemotherapy recurrent metastatic disease Prior adjuvant neoadjuvant chemotherapy ( include combination chemotherapy radiotherapy ) allow No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Chemotherapy No prior radiotherapy recurrent metastatic disease No prior radiotherapy 25 % bone marrow Prior adjuvant neoadjuvant radiotherapy allow More 4 week since prior radiotherapy No concurrent radiotherapy Surgery : More 4 week since prior abdominal exploration surgical resection More 3 week since prior abdominal exploration without surgical resection Other : No concurrent oral cryotherapy oxaliplatin administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>